Why it's time to speak up about antimicrobial resistance
25 May 2021
European Pharmaceutical Manufacturer editor Reece Armstrong looks at the antibiotics landscape and why we need to speak up about antimicrobial resistance (AMR).
In April this year, as the Covid-19 pandemic continued to dominate headlines across global media channels, the World Health Organisation (WHO) published its latest annual review evaluating the current clinical and preclinical pipelines for antibacterial candidates.
Conclusions from the report were stark, with WHO assistant director general on antimicrobial resistance (AMR), Dr Hanan Balkhy, saying that AMR is being fuelled by “the persistent failure to develop, manufacture, and distribute effective new antibiotics.”
A month prior, The Pew Trusts in the US updated its findings on the global pipeline of antibiotics and the conclusions were similar. With 43 antibiotics in clinical development - with some inevitably failing to win approval – it’s obvious that there are too few therapies in development to tackle the growing threat of AMR.
Of particular concern is how the larger pharmaceutical companies have completely taken themselves out of the picture when it comes to antibiotics. The Pew Trusts’ report says that of the 38 companies currently developing antibiotics, only two are classed as being among the top 50 pharma companies when it comes to commercial sales.
In 2016, AstraZeneca sold its antibiotics division to Pfizer in a deal worth over $500 million so it could focus on its three main therapy areas of respiratory & autoimmunity, cardiovascular & metabolic diseases, and oncology. Since then, the likes of Novartis, Sanofi and Allergen have exited the space to focus on disease areas which offer better return on investment (ROI).
The space then is dominated by smaller biotech companies, and with fewer resources than the major players, the market can be a volatile one to enter.
Biotech Achaogen gained regulatory approval from the FDA for its antibiotic plazomicin back in June 2018. Achaogen’s antibiotic was designed to treat complicated urinary tract infections (UTIs) caused by multidrug-resistant Enterobacteriaceae – a pathogen which is of critical priority for new antibiotics according to the WHO. However, a year later Achaogen was declaring bankruptcy and auctioning off its assets. It’s a story that has sadly been repeated by similar companies over the years and it’s a trend which points to one culprit as the catalyst.
The Market
Anyone following the discourse on antibiotics will know that for some time, pharmaceutical companies have been put off by the lack of ROI for developing new antibiotics. For instance, the Review on Antimicrobial Resistance chaired by Lord Jim O’Neill in 2014, shows that on average, it takes pharmaceutical companies 23 years to start achieving profitability for antibiotics.
Then there’s the looming threat of the patent life for antibiotics, or indeed any drug. When a new antibiotic launches onto the market, clinicians may be wary of using it lest resistance begins to develop. During this time, cheaper, generic antibiotics that still work against infections will be used instead. Indeed, the Review on Antimicrobial Resistance report states that whilst the total market for antibiotics is relatively large at $40 billion sales a year, only $4.7 billion of these sales come from patented antibiotics.
Compare this to oncology drugs for instance, which are used as first-line treatments once they reach the market and can make massive profits, and it’s understandable why pharma companies choose to invest elsewhere.
Next steps
With pharmaceutical developers put off from investing in new antibiotics, there is an obvious need for new solutions to incentivise the market so that new innovations can emerge.
For that to happen though, there needs be more interest put into the science underpinning antibiotic research – microbiology.
Lloyd Czaplewski, Chemical Biology Ventures’ director and someone who was on the advisory group for the WHO’s latest report sees the deficit of microbiologists as a major obstacle to antibiotic development.
“When I got into this space 20 years, most major pharma would have a team of 100 or 200 people working in the space – it’s all gone. That size and shape of team doesn’t exist in any one organisation any longer,” he tells me over a phone interview.
This has left antibiotic development work up to academics and a selection of biotechs, who don’t have a large enough portfolio to survive when a project fails.
“We don’t have the hundreds of people or thousands working in that space that we probably need for training, for career development, for longevity. Because you need to make fundamental discoveries to turn into new products. We don’t have enough of that,” Czaplewski adds.
It makes sense that there’s a deficit of microbiologist and infectious disease specialists. The Review on Antimicrobial Resistance highlights that in 2012, doctors in the US working in infectious diseases and HIV were the lowest paid compared to other medical fields. Move to 2021, and data from the National Residents Matching Program showed that 12% of infectious disease trainee positions in the US remain empty. For comparison, there were no positions left unfilled for oncology or pulmonary diseases in 2021.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.